SCHEMBL5524103

SCHEMBL5524103

CC(=O)C(CC1CCCCC1)C(=O)NCc1cccc([N+](=O)[O-])c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.54
KDM4E B2RXH2 1/20 0.51
ALDH1A1 P00352 1/20 0.51
PTPN1 P18031 1/20 0.45
OPRM1 P35372 1/20 0.45
OPRK1 P41145 1/20 0.45
EPHX1 P07099 2/20 0.44
CYP2C19 P33261 2/20 0.43
CYP2D6 P10635 1/20 0.43
CYP2C9 P11712 1/20 0.43
RECQL P46063 1/20 0.43
METAP2 P50579 1/20 0.43
METAP1 P53582 1/20 0.43
KMT2A Q03164 2/20 0.43
MEN1 O00255 1/20 0.43
F2RL1 P55085 2/20 0.42
ACKR3 P25106 1/20 0.42
KLKB1 P03952 1/20 0.42
CTSS P25774 1/20 0.42
CYP1A2 P05177 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5518446 0.88 POLB (0.50) POLBKDM4EALDH1A1PTPN1OPRM1
SCHEMBL5528540 0.78 EPHX1 (0.58) POLBKDM4EALDH1A1EPHX1CYP2C19
SCHEMBL5520892 0.75 EPHX1 (0.52) POLBKDM4EALDH1A1EPHX1CYP2C19
SCHEMBL584550 0.74 EPHX1 (0.73) POLBKDM4EALDH1A1PTPN1EPHX1
SCHEMBL30791550 0.74 PTPN1 (0.61) POLBALDH1A1PTPN1OPRM1OPRK1
SCHEMBL951041 0.74 PTPN1 (0.61) POLBALDH1A1PTPN1OPRM1OPRK1
SCHEMBL27587662 0.74 POLB (0.55) POLBKDM4EALDH1A1PTPN1OPRM1
SCHEMBL5520650 0.73 RAB9A (0.61) ALDH1A1EPHX1METAP2METAP1KMT2A
Hydrochloric Acid SCHEMBL5967103 0.73 CYP2D6 (0.55) ALDH1A1PTPN1OPRM1OPRK1CYP2C19
SCHEMBL5523092 0.72 MEN1 (0.56) POLBALDH1A1CYP2C19CYP2C9KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070232654-A1 Novel Compounds and Compositions as Cathepsin Inhibitors AXYS PHARMACEUTICALS, INC. (US) 2007-10-04 US disclosed
EP-1399146-A4 NOVEL COMPOUNDS AND COMPOSITIONS AS CATHEPSIN INHIBITORS AXYS PHARM INC (US) 2006-01-18 EP disclosed
US-20040147503-A1 Antiarthritic agents; muscular dystrophy; antiinflammatory agents; antitumor agents; glomerulonephritis AXYS PHARMACEUTICALS, INC. 2004-07-29 US disclosed
EP-1399146-A1 NOVEL COMPOUNDS AND COMPOSITIONS AS CATHEPSIN INHIBITORS AXYS PHARMACEUTICALS, INC. (US) 2004-03-24 EP disclosed
WO-2002098406-A1 NOVEL COMPOUNDS AND COMPOSITIONS AS CATHEPSIN INHIBITORS AXYS PHARMACEUTICALS, INC. (US) 2002-12-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070232654-A1 Novel Compounds and Compositions as Cathepsin Inhibitors CTSS, CTSB, CTSE POLB 2141/4885KDM4E 4386/4885ALDH1A1 4046/4885
US-20040147503-A1 Antiarthritic agents; muscular dystrophy; antiinflammatory agents; antitumor agents; glomerulonephritis CAPNS1, CTSS, CTSV POLB 2271/4885KDM4E 4064/4885ALDH1A1 3396/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.